Home » Exelixis Licenses PI3K-Delta Inhibitor R&D Program to Merck
Exelixis Licenses PI3K-Delta Inhibitor R&D Program to Merck
Exelixis licensed its PI3K-delta research and development program to Merck in order to focus on its lead compound cabozantinib, a potential cancer treatment.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May